{"id":817,"date":"2024-07-15T00:56:55","date_gmt":"2024-07-14T16:56:55","guid":{"rendered":"https:\/\/cytoarm.com\/?p=817"},"modified":"2024-09-09T08:54:56","modified_gmt":"2024-09-09T00:54:56","slug":"cytoarm-licenses-cd19-armed-t-cell-for-blood-cancer-drug-development-to-sl-link-company","status":"publish","type":"post","link":"https:\/\/cytoarm.com\/zh\/post\/817\/","title":{"rendered":"\u8cfd\u6602\u751f\u91ab\u6388\u6b0a CD19 Armed-T \u7d30\u80de\u9032\u884c\u8840\u764c\u85e5\u7269\u958b\u767c\u8207\u8ffd\u65e5\u6f64\u516c\u53f8\u5408\u4f5c"},"content":{"rendered":"<p><strong>Date:<\/strong> March 19, 2024<br><strong>Innovative Partnership for Advanced Cancer Therapy<\/strong><br>For more details, visit <a href=\"https:\/\/www.ctee.com.tw\/news\/20240319700569-431205\" target=\"_blank\" rel=\"noopener\">CTEE News<\/a>.<\/p>\n\n\n\n<p>SL-LINK Company has secured a license from CytoArm to develop the Armed-T cell therapy that targets blood cancers such as leukemia and multiple myeloma.<\/p>\n\n\n\n<p>CD-19 is a B cell surface antigen that is expressed during the early stages of B cell development and continues to be present through the cell&#8217;s lifespan. It is absent in most other cell types, making it an ideal target for therapies aimed at B cell malignancies. These cancers include:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Acute Lymphoblastic Leukemia (ALL)<\/strong>: A type of cancer that affects the blood and bone marrow, ALL is particularly aggressive and common in children.<\/li>\n\n\n\n<li><strong>Chronic Lymphocytic Leukemia (CLL)<\/strong>: A slower-growing cancer of the blood and bone marrow that typically affects older adults.<\/li>\n\n\n\n<li><strong>Diffuse Large B-Cell Lymphoma (DLBCL)<\/strong>: The most common type of non-Hodgkin lymphoma, characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs.<\/li>\n\n\n\n<li><strong>Follicular Lymphoma<\/strong>: A generally slow-growing type of non-Hodgkin lymphoma that arises from B cells.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"the-role-of-cd-19-in-cancer-therapy\">The Role of CD-19 in Cancer Therapy<\/h4>\n\n\n\n<p>The expression of CD-19 on B cells and its critical role in the pathogenesis of B-cell malignancies make it an attractive target for cancer therapy. Traditional treatments such as chemotherapy and radiation therapy, while effective to a degree, often come with significant side effects and are not always successful in eradicating the disease. This has led to the development of more targeted approaches, including CD-19 Armed-T cell therapy.<\/p>\n\n\n\n<p>The benefits of CD-19 Armed-T cell therapy are targeting patients who have exhausted all other treatment options. Ongoing development aims to improve the safety and efficacy of this treatment, making it more accessible and affordable. <\/p>","protected":false},"excerpt":{"rendered":"<p>Date: March 19, 2024Innovative Partnership for Advanced Cancer TherapyFor more details, visit CTEE News. SL-LINK Company has secured a license from CytoArm to develop the Armed-T cell therapy that targets blood cancers such as leukemia and multiple myeloma. CD-19 is a B cell surface antigen that is expressed during the early stages of B cell [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":818,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_gspb_post_css":"","footnotes":""},"categories":[20],"tags":[],"class_list":["post-817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-updates"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/posts\/817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/comments?post=817"}],"version-history":[{"count":0,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/posts\/817\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/media\/818"}],"wp:attachment":[{"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/media?parent=817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/categories?post=817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytoarm.com\/zh\/wp-json\/wp\/v2\/tags?post=817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}